

### **Listing of the Claims:**

1. (canceled) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. (canceled) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

3. (canceled) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence

identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. (canceled) The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5. (canceled) The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. (canceled) The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. (canceled) A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. (canceled) A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. (canceled) A recombinant host cell produced by the method of claim 8.

10. (canceled) The recombinant host cell of claim 9 comprising vector sequences.

11-12. (canceled)

13. (canceled) An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. (canceled)

15. (canceled) A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. (canceled) The polypeptide produced by claim 15.

17. (canceled)

18. (canceled) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. (canceled) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. (canceled) A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. (canceled) The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. (canceled) A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. (canceled)            The product produced by the method of claim 20.

24.    (previously presented) An isolated protein comprising amino acid residues 19 to 79 of SEQ ID NO:56.

25.    (previously presented) The isolated protein of claim 24 which comprises amino acid residues 2 to 79 of SEQ ID NO:56.

26.    (previously presented) The isolated protein of claim 24 which comprises amino acid residues 1 to 79 of SEQ ID NO:56.

27.    (previously presented) The protein of claim 24 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

28.    (previously presented) A composition comprising the protein of claim 24 and an acceptable carrier.

29.    (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 24 by a cell; and
- (b) recovering said protein.

30.    (previously presented) An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163.

31.    (previously presented) The isolated protein of claim 30 which comprises the amino acid sequence of the complete polypeptide encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163, excepting the N-terminal methionine.

32. (previously presented) The isolated protein of claim 30 which comprises the amino acid sequence of the complete polypeptide encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163.

33. (previously presented) The protein of claim 30 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

34. (previously presented) A composition comprising the protein of claim 30 and an acceptable carrier.

35. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 30 by a cell; and
- (b) recovering said protein.

36. (previously presented) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of amino acid residues 19 to 79 of SEQ ID NO:56, wherein said first polypeptide is capable of being used to generate or select an antibody that specifically binds the second polypeptide.

37. (previously presented) The isolated polypeptide of claim 36, wherein said first polypeptide is at least 95% identical to said second polypeptide.

38. (previously presented) The isolated first polypeptide of claim 36 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

39. (previously presented) A composition comprising the isolated first polypeptide of claim 36 and an acceptable carrier.

40. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the isolated first polypeptide of claim 36 by a cell; and
- (b) recovering said protein.

41. (previously presented) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of the secreted portion of the polypeptide encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163, wherein said first polypeptide is capable of being used to generate or select an antibody that specifically binds the second polypeptide.

42. (previously presented) The isolated first polypeptide of claim 41, wherein said first polypeptide is at least 95% identical to the said second polypeptide.

43. (previously presented) The isolated first polypeptide of claim 41 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

44. (previously presented) A composition comprising the isolated first polypeptide of claim 41 and an acceptable carrier.

45. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the isolated first polypeptide of claim 41 by a cell; and
- (b) recovering said protein.

46. (previously presented) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of amino acid residues 1 to 79 of SEQ ID NO:56, wherein said first polypeptide is capable of being used to generate or select an antibody that specifically binds the second polypeptide.

47. (previously presented) The isolated first polypeptide of claim 46, wherein said first polypeptide is at least 95% identical to said second polypeptide.

48. (previously presented) The isolated first polypeptide of claim 46 which comprises a heterologous polypeptide sequence.

49. (previously presented) A composition comprising the isolated first polypeptide of claim 46 and an acceptable carrier.

50. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the isolated first polypeptide of claim 46 by a cell; and
- (b) recovering said protein.

51. (previously presented) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of the complete polypeptide encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163, wherein said first polypeptide is capable of being used to generate or select an antibody that specifically binds the second polypeptide.

52. (previously presented) The isolated first polypeptide of claim 51, wherein said first polypeptide is at least 95% identical to said second polypeptide.

53. (previously presented) The isolated first polypeptide of claim 51 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

54. (previously presented) A composition comprising the isolated first polypeptide of claim 51 and an acceptable carrier.

55. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the isolated first polypeptide of claim 51 by a cell; and
- (b) recovering said protein.

56. (previously presented) An isolated protein consisting of at least 30 contiguous amino acid residues of amino acid residues 19 to 79 of SEQ ID NO:56, wherein said protein is capable of being used to generate or select an antibody that specifically binds a polypeptide comprised of amino acid residues 19 to 79 of SEQ ID NO:56.

57. (previously presented) The isolated protein of claim 56 which consists of at least 50 contiguous amino acid residues of amino acid residues 19 to 79 of SEQ ID NO:56.

58. (previously presented) The protein of claim 56 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

59. (previously presented) A composition comprising the protein of claim 56 and an acceptable carrier.

60. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 56 by a cell; and
- (b) recovering said protein.

61. (previously presented) An isolated protein consisting of at least 30 contiguous amino acid residues of the secreted portion of the protein encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163, wherein said first protein is capable of being used to generate or select an antibody that specifically binds the second protein.

62. (previously presented) The isolated protein of claim 61 which consists of at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163.

63. (previously presented) The protein of claim 61 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

64. (previously presented) A composition comprising the protein of claim 61 and an acceptable carrier.

65. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 61 by a cell; and
- (b) recovering said protein.



66. (previously presented) An isolated protein consisting of at least 30 contiguous amino acid residues of amino acid residues 1 to 79 of SEQ ID NO:56, wherein said protein is capable of being used to generate or select an antibody that specifically binds a polypeptide comprised of amino acid residues 1 to 79 of SEQ ID NO:56.

67. (previously presented) The isolated protein of claim 66 which consists of at least 50 contiguous amino acid residues of amino acid residues 1 to 79 of SEQ ID NO:56.

68. (previously presented) The protein of claim 66 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

69. (previously presented) A composition comprising the protein of claim 66 and an acceptable carrier.

70. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 66 by a cell; and
- (b) recovering said protein.

71. (previously presented) An isolated protein consisting of at least 30 contiguous amino acid residues of the complete protein encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163, wherein said first protein is capable of being used to generate or select an antibody that specifically binds the second protein.

72. (previously presented) The isolated protein of claim 71 which consists of at least 50 contiguous amino acid residues of the complete polypeptide encoded by the HYACJ27 cDNA contained in ATCC Deposit No. PTA-163.

73. (previously presented) The protein of claim 71 which further comprises a polypeptide sequence heterologous to SEQ ID NO:56.

74. (previously presented) A composition comprising the protein of claim 71 and an acceptable carrier.

75. (previously presented) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 71 by a cell; and
- (c) recovering said protein.

76. (canceled) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.